logo
Book a meeting
Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals

Pharmaceuticals, 51 W 69th St, Melbourne, New York, 10023, United States, 11-50 Employees

paradigmbiopharma.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: +15*********

Who is PARADIGM BIOPHARMACEUTICALS

Paradigms (ASX:PAR) immediate commercial focus is the development of pentosan polysulfate sodium (PPS) for the treatment of osteoarthritis (OA). This is a global unmet need and we have ad...

Read More

lock icon Get Full Access
map
  • 51 W 69th St, Melbourne, New York, 10023, United States Headquarters: 51 W 69th St, Melbourne, New York, 10023, United States
  • 2014 Date Founded: 2014
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

checked-icon Does something look wrong? Fix it. | View contact records from PARADIGM BIOPHARMACEUTICALS

Paradigm Biopharmaceuticals Org Chart and Mapping

Employees
Paul Lapchak

Paul Lapchak

Global Head of Translational Development

Mike Sheehan

Mike Sheehan

Senior Director, Clinical Operations

David Heilig

David Heilig

Clinical Operations Lead

See Full Org Chart arrow
email-formate-icon
View Email Formats for Paradigm Biopharmaceuticals
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding Paradigm Biopharmaceuticals

Answer: Paradigm Biopharmaceuticals's headquarters are located at 51 W 69th St, Melbourne, New York, 10023, United States

Answer: Paradigm Biopharmaceuticals's phone number is +15*********

Answer: Paradigm Biopharmaceuticals's official website is https://paradigmbiopharma.com

Answer: Paradigm Biopharmaceuticals's revenue is $5 Million to $10 Million

Answer: Paradigm Biopharmaceuticals has 11-50 employees

Answer: Paradigm Biopharmaceuticals is in Pharmaceuticals

Answer: Paradigm Biopharmaceuticals contact info: Phone number: +15********* Website: https://paradigmbiopharma.com

Answer: Paradigms (ASX:PAR) immediate commercial focus is the development of pentosan polysulfate sodium (PPS) for the treatment of osteoarthritis (OA). This is a global unmet need and we have advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain, and regeneration, the non-opioid PPS has genuine disease-modifying potential.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access